IGM Biosciences Inc. is a biotechnology company that specializes in the development of novel immunoglobulin M (IgM) antibodies for the treatment of cancer. The company was founded in 2010 and is headquartered in Mountain View, California, United States.
IGM Biosciences focuses on the discovery and development of engineered IgM antibodies, leveraging its proprietary technology platform called IgM antibody technology. These antibodies are designed to enhance the therapeutic potential of immunotherapies by targeting multiple disease pathways simultaneously. IgM antibodies have unique properties that make them suitable for treating various types of cancer.
The company's pipeline includes several investigational product candidates, such as IGM-2323, IGM-8444, and IGM-7354, which are being developed for the treatment of hematologic malignancies and solid tumors. These candidates are designed to target specific cancer antigens and engage the immune system to fight against cancer cells.
IGM Biosciences went public on the NASDAQ stock exchange on March 28, 2019, under the ticker symbol "IGMS." The initial public offering (IPO) allowed the company to raise funds to support its research and development efforts and advance its pipeline of product candidates.
Since going public, IGM Biosciences has continued to advance its product candidates through preclinical and clinical development stages. The company has entered into partnerships and collaborations with other biopharmaceutical companies to further its research and expand its reach in the field of cancer immunotherapy.
IGM Biosciences is dedicated to developing innovative antibody-based therapies for patients with cancer. Through its focus on IgM antibodies and its robust pipeline, the company aims to address unmet medical needs and make a meaningful impact in the field of oncology.